Bibliography

Back to Publications
    1. O’Connor CM, Psotka MA, Fiuzat M, et al. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol. 2018;71(4):443-453. doi:10.1016/j.jacc.2017.11.048.
    2. O’Connor CM, Bristow MR. Changing the Research Culture in the United States. JACC Heart Fail. 2018;6(4):344-345. doi:10.1016/j.jchf.2018.03.001.
    3. Tahhan AS, Vaduganathan M, Greene SJ, et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol. 2018;3(10):1011-1019. doi:10.1001/jamacardio.2018.2559.
    4. Butler J, Packer M, Greene SJ, et al. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019;140(25):2108-2118. doi:10.1161/CIRCULATIONAHA.119.042155.
    5. Psotka MA, Fiuzat M, Carson PE, et al. Design of a “Lean” Case Report Form for Heart Failure Therapeutic Development. JACC Heart Fail. 2019;7(11):913-921. doi:10.1016/j.jchf.2019.07.001.
    6. Abraham WT, Psotka MA, Fiuzat M, et al. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC Heart Fail. 2020;8(12):961-972. doi:10.1016/j.jchf.2020.10.002.
    7. Abraham WT, Fiuzat M, Psotka MA, O’Connor CM. Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19. JACC Heart Fail. 2020;8(5):423-425. doi:10.1016/j.jchf.2020.03.005.
    8. Fiuzat M, Lowy N, Stockbridge N, et al. Endpoints in Heart Failure Drug Development. JACC Heart Fail. 2020;8(6):429-440. doi:10.1016/j.jchf.2019.12.011.
    9. Psotka MA, Latta F, Cani D, et al. Publication Rates of Heart Failure Clinical Trials Remain Low. JACC. 2020;75(25):3151-3161. doi:10.1016/j.jacc.2020.04.068.
    10. O’Connor CM, Bristow MR. Changing U.S. Heart Failure Research Culture: Part 2—Recognizing Frontline Investigators and Coordinators. JACC Heart Fail. 2020;8(12):1050-1051. doi:10.1016/j.jchf.2020.10.010.
    11. Perego C, Sbolli M, Specchia C, et al. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. JACC Heart Fail. 2020;8(12):973-983. doi:10.1016/j.jchf.2020.07.005.
    12. Psotka MA, Abraham WT, Fiuzat M, et al. Conduct of Clinical Trials in the Era of COVID-19. JACC. 2020;76(20):2368-2378. doi:10.1016/j.jacc.2020.09.544.
    13. Psotka MA, Fiuzat M, Solomon SD, et al. Challenges and Potential Improvements to Patient Access to Pharmaceuticals. Circulation. 2020;142(8):790-798. doi:10.1161/CIRCULATIONAHA.119.044976.
    14. Reza N, Tahhan AS, Mahmud N, et al. Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circ Heart Fail. 2020;13(8):e006605. doi:10.1161/CIRCHEARTFAILURE.119.006605.
    15. Sinha SS, Psotka MA, Fiuzat M, et al. Barriers to Clinical Trial Efficiency and Patient Access: The Heart Failure Collaboratory Industry Survey. medRxiv. Preprint posted online June 29, 2020:2020.06.24.20124917. doi:10.1101/2020.06.24.20124917.
    16. Anchouche K, Elharram M, Oulousian E, et al. Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review. Can J Cardiol. 2021;37(9):1438-1449. doi:10.1016/j.cjca.2021.07.001.
    17. Bhatt AS, Abraham WT, Lindenfeld J, et al. Treatment of HF in an Era of Multiple Therapies. JACC Heart Fail. 2021;9(1):1-12. doi:10.1016/j.jchf.2020.10.014.
    18. Bhatt AS, Jering KS, Vaduganathan M, et al. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. JACC Heart Fail. 2021;9(1):65-73. doi:10.1016/j.jchf.2020.11.003.
    19. DeFilippis EM, Fiuzat M. Putting the “Optimal” in Optimal Medical Therapy∗. JACC Heart Fail. 2021;9(1):39-41. doi:10.1016/j.jchf.2020.08.016.
    20. Lindenfeld J, Fiuzat M, O’Connor C. Promoting Diversity in Clinical Trial Leadership: A Call to Action. JACC Heart Fail. 2021;9(5):401-402. doi:10.1016/j.jchf.2021.03.005.
    21. Butt JH, Dewan P, DeFilippis EM, et al. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score. JACC Heart Fail. 2022;10(8):543-555. doi:10.1016/j.jchf.2022.03.009.
    22. DeFilippis EM, Echols M, Adamson PB, et al. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. JAMA Cardiol. 2022;7(5):540-548. doi:10.1001/jamacardio.2022.0161.
    23. Fiuzat M, Hamo CE, Butler J, et al. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79(5):504-510. doi:10.1016/j.jacc.2021.11.033.
    24. Lala A, O’Connor CM, Fiuzat M, Drazner MH, Mentz RJ. Recognizing Efforts that Support Clinical Trial Success: Site-Based Research Awards from the Heart Failure Collaboratory and Heart Failure Society of America. J Card Fail. 2022;28(9):1387-1389. doi:10.1016/j.cardfail.2022.08.001.
    25. Ostrominski JW, Hirji S, Bhatt AS, et al. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC Heart Fail. 2022;10(1):1-11. doi:10.1016/j.jchf.2021.08.002.
    26. Psotka MA, Abraham WT, Fiuzat M, et al. Functional and Symptomatic Clinical Trial Endpoints. JACC Heart Fail. 2022;10(12):889-901. doi:10.1016/j.jchf.2022.09.012.
    27. Bhatt AS, Dimond M, Fiuzat M, et al. Impact of COVID-19 on Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory. JACC Heart Fail. 2023;11(2):254-257. doi:10.1016/j.jchf.2022.11.024.
    28. Dimond MG, Fiuzat M, Mentz RJ, et al. Rewarding Site-Based Research. JACC Heart Fail. 2024;12(1):226-228. doi:10.1016/j.jchf.2023.07.032.
    29. Johansen ND, Vaduganathan M, Zahir D, et al. A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study. Circ Heart Fail. 2023;16(2):e009729. doi:10.1161/CIRCHEARTFAILURE.122.009729
    30. Yehya A. Recognizing Physicians Beyond Revenue Value Units. J Card Fail. 2024;30(1):117-118. doi:10.1016/j.cardfail.2023.09.004. 
    31. Psotka MA. Step by Step. JACC Heart Fail. 2023;11(11):1531-1533. doi:10.1016/j.jchf.2023.06.016.
    32. Lala A, Hamo CE, Bozkurt B, et al. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies. JACC Heart Fail. 2024;12(1):1-15. doi:10.1016/j.jchf.2023.09.030.
    33. Blumer V, Bogaev RC, Fiuzat M. Sex Diversity in Heart Failure Clinical Trials. JACC Adv. 2024;3(1):100786. doi:10.1016/j.jacadv.2023.100786.
    34. Dimond MG, Ibrahim NE, Fiuzat M, et al. Left ventricular ejection fraction and the future of heart failure phenotyping. JACC Heart Fail. 2024;12(3):451-460. doi:10.1016/j.jchf.2023.11.005 
    35. Adamson PB, Echols M, DeFilippis EM, et al. Clinical trial inclusion and impact on early adoption of medical innovation in diverse populations. JACC Heart Fail. 2024;12(7):1212-1222. doi:10.1016/j.jchf.2024.02.015.
    36. Fleming TR, Wittes J, Fiuzat M, et al. Training the next generation of data monitoring committee members: an initiative of the Heart Failure Collaboratory. JACC Heart Fail. 2024;12(8):1317-1327. doi:10.1016/j.jchf.2024.02.016
    37. Bhatt AS, Fiuzat M. How did we score? Evaluating the utility of a score-based system for heart failure medical therapy. Circ Heart Fail. 2024;17(5):e011654. doi:10.1161/CIRCHEARTFAILURE.124.011654..
    38. Blumer V, Januzzi JL Jr, Lindenfeld J, et al. Heart failure drug development over the eras: from the Heart Failure Collaboratory. JACC Heart Fail. 2024;12(11):1803-1813. doi:10.1016/j.jchf.2024.03.021
    39. Rao VN, Hellkamp AS, Thomas LE, et al. Optimal medical therapy and outcomes among patients with chronic heart failure with reduced ejection fraction. JACC Heart Fail. 2024;12(11):1862-1875. doi:10.1016/j.jchf.2024.05.026.
    40. Bhatt AS, Chatur S, Claggett BL, et al. Gamified behavioral science intervention to enhance trial enrollment. JACC Heart Fail. 2024;12(11):1939-1941.
    41. Reza N, Fiuzat M, Konstam MA. Measures to improve trial enrollment: it’s game time! JACC Heart Fail. 2024;12(11):1942-1945. doi:10.1016/j.jchf.2024.08.006.
    42. Cunningham JW, Abraham WT, Bhatt AS, et al. Artificial intelligence in cardiovascular clinical trials. J Am Coll Cardiol. 2024;84(20):2051-2062. doi:10.1016/j.jacc.2024.08.069.
    43. Evans Y, Fiuzat M, Jessup M, et al. Rewarding site-based research: the unsung heroes of heart failure clinical research. Circ Heart Fail. 2024;17(11):e012481. doi:10.1161/CIRCHEARTFAILURE.124.012481.
    44. Shalowitz EL, Jhund PS, Psotka MA, et al. Where’s the remote? Failure to report clinical workflows in heart failure remote monitoring studies. J Card Fail. 2025;31(9):1420-1429
    45. Lala A, Coca S, Feinman J, et al. Standardized definitions of changes in kidney function in trials of heart failure: JACC Expert Panel from the HF-ARC. J Am Coll Cardiol. 2025;85(7):766-781. doi:10.1016/j.jacc.2024.11.041.
    46. Fiuzat M, Ferlin K, Gottschalk L, et al. An innovative program for evidence generation: HFC perspective on the FDA Total Product Life Cycle Advisory Program. JACC Heart Fail. 2025;13(4):647-650. doi:10.1016/j.jchf.2025.01.011.
    47. Cavagna I, Fiuzat M, Lala A, et al. Inertia is not an option: laying the foundation for a consensus on the assessment of kidney function in acute decompensated heart failure. J Card Fail. 2025;31(6):953-956.
    48. Cunningham JW, O’Connor CM. The future of artificial intelligence–assisted event adjudication. JACC Heart Fail. 2025;13(5):722-724. doi:10.1016/j.jchf.2025.03.015.
    49. Butler J, Usman MS, Gandotra C, et al. Patient-reported outcomes as end points in heart failure trials. Circulation. 2025;151(15):1111-1125. doi:10.1161/CIRCULATIONAHA.124.072158.
    50. Mann DL, Felker GM, Unger EF, et al. Derisking phase II clinical trials in heart failure: a position paper from JACC: Basic to Translational Science and the Heart Failure Collaboratory. JACC Basic Transl Sci. 2025;10(5):677-688. doi:10.1016/j.jacbts.2025.04.003.
    51. Leifer ES, Troendle JF, Psotka MA, Sachdev V. Hierarchical analysis of composite time-to-event end points in heart failure clinical trials using time in clinical state. Circ Heart Fail. 2025;18(7). doi:10.1161/CIRCHEARTFAILURE.124.011783.
    52. DeFilippis EM, Blumer V, Makuvire TT, et al. Social drivers of health in heart failure trials: an analysis from the Heart Failure Collaboratory. JACC Heart Fail. 2025;13(9):102546. doi:10.1016/j.jchf.2025.102546.
    53. Fiuzat M, Butler J, Stockbridge N, et al. Background therapy for HF clinical trials: a randomized crossover debate from the Heart Failure Collaboratory. JACC Heart Fail. 2025;13(10):102596. doi:10.1016/j.jchf.2025.102596.
    54. Armbruster S, McCaw ZR, Jering K, et al. Capturing totality of treatment effects: a model-free approach to analyzing multiple event-time data from heart failure studies. JACC Heart Fail. 2025;13(10):102605. doi:10.1016/j.jchf.2025.102605.
    55. Blumer V, Lindenfeld J, Lala A, et al. Let us call it cardiogenic preshock: a working definition from the Heart Failure Collaboratory. J Am Coll Cardiol. 2025;86(11):832-835. doi:10.1016/j.jacc.2025.07.017.
    56. Bhatt AS, De Oliveira-Gomes D, Fiuzat M, et al. Assessing medical therapy optimization in cardiovascular-kidney-metabolic clinical trials: an initiative from the Heart Failure Collaboratory. JACC Heart Fail. 2026;14(3):102727. doi:10.1016/j.jchf.2025.102727.
    57. Rivera AD, Fiuzat M, Bristow MR, et al. Backbone of trials in a challenging environment: recognizing site-based research teams. Circ Heart Fail. 2025;18(11):e013821. doi:10.1161/CIRCHEARTFAILURE.125.013821.
    58. Gupta M, Fiuzat M, Dimond M, et al. Promoting representation in heart failure clinical trials: recommendations from the Heart Failure Collaboratory. JACC Heart Fail. 2025;13(7):102485. doi:10.1016/j.jchf.2025.03.033.
    59. Kose O, Sahal A, Zhang GK, et al. Framework for analytical validation of DHT-based actigraphy and signal measures in HF trials: the VALIDATE-HF program. JACC Heart Fail. 2026;14(4):102831. doi:10.1016/j.jchf.2025.102831.
    60. Blumer V, Bozkurt B, Konstam MA, et al. Subgroups and special populations in heart failure clinical trials: insights from the HFC-ARC Expert Consensus Panel. JACC Heart Fail. 2026;14(4):102775. doi:10.1016/j.jchf.2025.102775.
    61. Shalowitz EL, Jhund PS, Psotka MA, et al. Standardized reporting in heart failure noninvasive remote monitoring trials: interventions to catalyze data into action. JACC Heart Fail. 2026;14(5):102849. doi:10.1016/j.jchf.2025.102849.
    62. Krantz MJ, Senatore F, Psotka MA, et al. Heart failure endpoints in Food and Drug Administration pivotal trials. Eur Heart J. 2026;47(19):2245-2254. doi:10.1093/eurheartj/ehag069
    63. Fiuzat M, O’Connor CM, Mann DL. In memoriam: Michael R. Bristow, MD, PhD. J Card Fail. 2026;32(3):688-690. doi:10.1016/j.cardfail.2026.01.003.
    64. McCallum W, Tighiouart H, Tuttle M, et al. Association of the timing of acute declines in kidney function in acute heart failure with cardiovascular and kidney outcomes. Am J Kidney Dis. 2026;87(6):808-819.e1. doi:10.1053/j.ajkd.2025.12.005.
    65. Batchelor WB, Califf R, Mehran R, et al. Aligning coronary stent trial enrollment with the U.S. intended-use population: implications of site selection. J Am Coll Cardiol. 2026;87(16):2163-2176. doi:10.1016/j.jacc.2026.01.088.
    66. Pan T, Tian L, Claggett B, et al. Bayesian counterparts to the frequentist Kaplan-Meier estimate and its summary measures for comparative heart failure clinical studies. J Card Fail. 2026;32(7):1238-1245. doi:10.1016/j.cardfail.2026.02.046.
    67. Rivera AD, Psotka MA, Fiuzat M, O’Connor CM; Heart Failure Collaboratory. Forty years of heart failure drug clinical trials: have we made progress on enrollment? JACC Heart Fail. 2026;14(8):103068. doi:10.1016/j.jchf.2026.103068.
    68. Echols MR, Fiuzat M, Brinkley DM, et al. Rebuilding U.S. heart failure site-based research: a national expert authority blueprint from the Heart Failure Collaboratory. JACC Heart Fail. Published online June 17, 2026. doi:10.1016/j.jchf.2026.103165.
    69. Blumer V, Wittes JT, Pomeroy JE, et al. Select contemporary statistical concepts in heart failure clinical trials: insights from the Heart Failure Collaboratory. JACC Heart Fail. Published online June 26, 2026. doi:10.1016/j.jchf.2026.103180.
    70. Makker S, Badrouchi S, Xu D, et al. Clinical trial source document verification using a large language model. JACC Adv. 2026;5(9):103108. doi:10.1016/j.jacadv.2026.103108
    71. Guilliod CR, Blumer V, De Oliveira-Gomes D, et al. Demographic enrollment by region in heart failure trials: insights from GUIDE-IT and HF-ACTION. J Card Fail. Published online July 16, 2026. doi:10.1016/j.cardfail.2026.07.004